Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Find generic entry opportunities
Anticipate generic drug launch
|Abstract:||The invention relates to C.sub.2-20 alkanoic acid esters of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6, 7,8,9-tetrahydro-9-hydroxy-2 -methyl-4H-pyrido[1,2-a]pyrimidin-4-one, pharmaceutically acceptable acid addition salts thereof, and enantiomeric forms thereof, which are useful in the treatment of warm-blooded animals suffering from psychotic diseases.|
|Inventor(s):||Janssen; Cornelus G. M. (Vosselaar, BE), Knaeps; Alfonsus G. (Herentals, BE), Kennis; Ludo E. J. (Turnhout, BE), Vandenberk; Jan (Beerse, BE)|
|Assignee:||Janssen Pharmaceutica N.V. (Beerse, BE)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.